Related Experiment Video
Updated: Dec 20, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.0K
Bempedoic acid: a promising novel agent for LDL-C lowering
Anandita Agarwala1, Anne C Goldberg2
1Division of Cardiology, Washington University School of Medicine, 660 S. Euclid, Campus Box 8086, St Louis, MO 63110, USA.
Future Cardiology
|May 29, 2020
Summary
Bempedoic acid is a new oral medication that lowers LDL cholesterol by inhibiting cholesterol synthesis. It shows promise for patients with statin intolerance and those at high cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Bempedoic acid (ETC-1002) is a novel oral small molecule inhibitor of cholesterol biosynthesis.
- It targets the ATP-citrate lyase (ACL) enzyme, upstream of HMG-CoA reductase targeted by statins.
- This mechanism upregulates LDL receptors, leading to reduced LDL-C levels.
Purpose of the Study:
- To review the development and clinical trial data of bempedoic acid.
- To evaluate its safety and efficacy in lowering LDL-C.
- To discuss its potential role in managing dyslipidemia, particularly in statin-intolerant patients.
Main Methods:
- Review of preclinical data and completed Phase II and III clinical trials.
- Analysis of efficacy and safety profiles across diverse patient populations.
- Consideration of bempedoic acid in the context of existing lipid-lowering therapies.
Main Results:
- Preclinical and clinical trials demonstrate promising safety and efficacy of bempedoic acid.
- Effective LDL-C reduction observed in various patient groups, including those with statin intolerance.
- Ongoing cardiovascular outcomes trial to assess impact on major adverse cardiovascular events.
Conclusions:
- Bempedoic acid represents a novel therapeutic option for lowering LDL-C.
- Its efficacy and safety profile support its use, especially in statin-intolerant patients.
- Further evaluation in outcomes trials will define its role in cardiovascular risk reduction.
Keywords:
LDL cholesterolatherosclerotic cardiovascular diseasebempedoic acidcholesterolezetimibelipid-lowering therapynonstatin therapypreventionstatinsMore Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
01:26Atherosclerosis III: Management
259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
01:23Antidepressant Drugs: MAOIs and Other Agents
688
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
688
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:27Bioavailability Enhancement: Drug Permeability Enhancement
134
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
134
01:24Lipid Absorption
2.3K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.3K